Sabra Health Care REIT exceeded Q2 2025 analyst expectations with strong performance in managed senior housing, reporting normalized FFO of $0.37 per share and revenue of $189.15 million, representing a 7.4% year-over-year increase.

The headline numbers for Sabra (SBRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evaluate the expected performance of Sabra (SBRA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said if you are looking for a stock that’s on the verge of breaking out, Deere & Company (NYSE: DE). On March 25, Deere & Company said former Eastman Chemical Company executive, Kellye Walker, will join its leadership team as senior vice president, chief legal officer and worldwide public affairs, effective April 29. Stephen Weiss of Short Hills Capital Partners picked ASML Holding N.V. (NASDAQ: ASML), saying that ...

The headline numbers for Sabra (SBRA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sabra (SBRA) delivered FFO and revenue surprises of -2.94% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Beyond analysts' top -and-bottom-line estimates for Sabra (SBRA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

National Health Investors reported strong Q4-2023 results, beating revenue and funds from operations estimates. Learn why NHI stock is a Hold.

Alexander's (ALX) delivered FFO and revenue surprises of -16.13% and 13.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management said Sabra Health Care REIT, Inc. (NASDAQ: SBRA) has a 9% yield and 5% earnings growth. Deutsche Bank analyst Omotayo Okusanya initiated coverage on Sabra Health Care REIT with a Buy rating and announced a price target of $21. Sabra Health Care recently named Jessica Flores as executive vice president and chief accounting officer. Josh Brown of Ritholtz Wealth Management picked The Goldman Sachs ...

In the preceding three months, 5 analysts have released ratings for Sabra Health Care REIT (NASDAQ:SBRA), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 3 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.8, a high estimate of $17.00, and a low estimate of $15.00. This current average reflects an increase of 12.86% from the previous average price target of $14.00. Diving into Analyst Ratings: An In-Depth Exploration A clear picture of Sabra Health Care REIT's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Vikram Malhotra Mizuho Raises Buy $17.00 $15.00 Stephen Manaker Stifel Raises Buy $16.00 $14.00 Connor Siversky Wells Fargo Raises Equal-Weight $15.00 $13.00 John Kim BMO Capital Announces Market Perform $16.00 - Connor Siversky Wells Fargo Announces Equal-Weight $15.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ...Full story available on Benzinga.com

Smart Beta ETF report for KBWY